Get the Stockscreener App
6.80
2.30%
-0.16
Nuvectis Pharma Inc stock is traded at $6.80, with a volume of 98,316.
It is down -2.30% in the last 24 hours and down -6.98% over the past month.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$6.96
Open:
$6.91
24h Volume:
98,316
Relative Volume:
0.67
Market Cap:
$142.08M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-4.8227
EPS:
-1.41
Net Cash Flow:
$-15.54M
1W Performance:
-12.60%
1M Performance:
-6.98%
6M Performance:
+0.59%
1Y Performance:
+10.03%
1-Day Range:
$6.75
$6.95
1-Week Range:
$6.3039
$7.95
52-Week Range:
$4.44
$11.80
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Name
Nuvectis Pharma Inc
Sector
Industry
Phone
360-837-7232
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.80 | 145.42M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-02-25 | Initiated | Maxim Group | Buy |
| Mar-17-25 | Initiated | Laidlaw | Buy |
| Jul-13-22 | Initiated | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Stock (NVCT) Latest News
Will a bounce in Nuvectis Pharma Inc. offer an exitFree Oversold Bounce Stock Play Ideas - Newser
Volume spikes in Nuvectis Pharma Inc. stock – what they meanAI Triggered Buy Zone Forecast System - Newser
How to read the order book for Nuvectis Pharma Inc.Pattern Breakout Prediction for Short Term - Newser
Will Nuvectis Pharma Inc. benefit from macro trendsDaily Exit and Entry Price Prediction - Newser
Key resistance and support levels for Nuvectis Pharma Inc.Pattern Recognition Tool for ROI Investors - Newser
Using R and stats models for Nuvectis Pharma Inc. forecastingPattern Recognition Tool for ROI Investors - Newser
Nuvectis Pharma Provides Final Clinical Data Update from - GlobeNewswire
Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drug - Endpoints News
Is Nuvectis Pharma Inc. a growth stock or a value stockExpert Picks Review With Low Risk - jammulinksnews.com
Nuvectis Pharma Plunges 15.1% on NXP800 Halt - AInvest
Nuvectis halts NXP800 development for ovarian cancer, shifts focus By Investing.com - Investing.com Nigeria
Is it time to cut losses on Nuvectis Pharma Inc.Earnings Report Summary with Market Impact - Newser
What makes Nuvectis Pharma Inc. stock price move sharplyInvestment Position Summary with Timeframe Forecast - Newser
Exit strategy if you’re trapped in Nuvectis Pharma Inc.Asset Safety Selection Using Quantitative Analysis - Newser
Why Nuvectis Pharma Inc. stock attracts strong analyst attentionSmart Risk Strategy with Entry Optimization - Newser
Real time scanner hits for Nuvectis Pharma Inc. explainedFree Quick Gain Stock Watch With Indicators - Newser
Nuvectis Pharma Inc. Volume Confirms Breakout — Analysts BullishTrade Setups With Clear Risk Limits Highlighted - metal.it
Published on: 2025-07-29 06:16:31 - Newser
How strong is Nuvectis Pharma Inc. company’s balance sheetStock Market Picks With High Returns - jammulinksnews.com
Why is Nuvectis Pharma Inc. stock attracting strong analyst attentionMarket-beating performance - jammulinksnews.com
Exit strategy if you’re trapped in Nuvectis Pharma Inc. Stable Profit Zone and Loss Control Analysis - Newser
Real time scanner hits for Nuvectis Pharma Inc. explained Top Stock Picks with Forecast Accuracy - Newser
What institutional investors are buying Nuvectis Pharma Inc. stockEarnings Report Ideas With High Returns - jammulinksnews.com
Does Nuvectis Pharma Inc. stock perform well during market downturnsGrow your portfolio with growth-oriented stocks - jammulinksnews.com
What is Nuvectis Pharma Inc. company’s growth strategyCapitalize on market trends with confidence - jammulinksnews.com
What is the dividend policy of Nuvectis Pharma Inc. stockExplosive earnings growth - jammulinksnews.com
When is Nuvectis Pharma Inc. stock expected to show significant growthPowerful market insights - jammulinksnews.com
Published on: 2025-07-28 00:51:34 - jammulinksnews.com
Nuvectis Pharma Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingChart Breakout Alert - Newser
Why Nuvectis Pharma Inc. stock is on top investor watchlistsSkyrocketing investment returns - jammulinksnews.com
Nuvectis Pharma Inc. Stock Analysis and ForecastSuperior returns - Autocar Professional
What drives Nuvectis Pharma Inc. stock priceRecord-breaking capital gains - Autocar Professional
Nuvectis Pharma Inc Stock (NVCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nuvectis Pharma Inc Stock (NVCT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mosseri Marlio Charles | 10% Owner |
Jun 18 '25 |
Buy |
8.05 |
28,043 |
225,746 |
2,976,203 |
| Mosseri Marlio Charles | 10% Owner |
Jun 17 '25 |
Buy |
8.11 |
5,399 |
43,786 |
2,948,160 |
| Mosseri Marlio Charles | 10% Owner |
May 12 '25 |
Buy |
8.11 |
21,167 |
171,664 |
2,942,761 |
| Mosseri Marlio Charles | 10% Owner |
May 06 '25 |
Buy |
8.59 |
12,444 |
106,955 |
2,896,565 |
| Mosseri Marlio Charles | 10% Owner |
May 07 '25 |
Buy |
8.59 |
12,317 |
105,770 |
2,908,882 |
| Mosseri Marlio Charles | 10% Owner |
May 08 '25 |
Buy |
8.65 |
2,650 |
22,922 |
2,911,532 |
| Mosseri Marlio Charles | 10% Owner |
Feb 07 '25 |
Buy |
5.00 |
240,000 |
1,200,000 |
2,884,121 |
| BENTSUR RON | Chairman & CEO |
Dec 24 '24 |
Buy |
4.65 |
4,500 |
20,925 |
3,270,924 |
| Mosseri Marlio Charles | 10% Owner |
Dec 13 '24 |
Buy |
4.70 |
17,000 |
79,900 |
2,612,000 |
| Poradosu Enrique | Chief Science & Business Off |
Nov 19 '24 |
Buy |
4.99 |
2,000 |
9,980 |
1,506,319 |
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):